

## Establishment of cell lines latently infected with non-oncogenic murine gammaherpesvirus 76

Z. HRABOVSKÁ<sup>1</sup>, A. CHALUPKOVÁ<sup>1</sup>, J. ČÍPKOVÁ<sup>1</sup>, J. MISTRÍKOVÁ<sup>1,2\*</sup>

<sup>1</sup>Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University, Mlynská dolina CH-2, 842 15 Bratislava, Slovak Republic; <sup>2</sup>Institute of Virology, Slovak Academy of Sciences, Dúbravská cesta 9, 845 05 Bratislava, Slovak Republic

Received July 23, 2010; accepted August 25, 2010

**Summary.** – Murine gammaherpesviruses 68 (MHV-68) and 78 (MHV-78), both inducing tumors in mice and a latent infection in cells *in vitro*, serve as models for study of human oncogenic gammaherpesviruses, namely Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV). In this work, we succeeded in establishing a latent infection of HeLa and CGL1 cell lines with non-oncogenic murine gammaherpesvirus 76 (MHV-76), which differs from MHV-68 and MHV-78 besides by oncogenicity also by deletion of M1-M4 genes and eight tRNA-like sequences. Viral latency in these cell lines,  $\lambda$ HeLa and  $\lambda$ CGL1, was demonstrated by the presence of viral DNA, suppression of viral latency-associated ORF73 gene and appearance of low amounts of infectious virus following treatment with phorbol 12-myristate 13-acetate (PMA). Both latently infected cell lines showed irregular presence of viral antigen originating apparently from spontaneous reactivation. The growth of latently infected cells in culture was similar to that of non-infected ones. The latently-infected  $\lambda$ HeLa cells did not induce tumors in mice following subcutaneous inoculation. These results (i) confirm that MHV-76 is the only non-oncogenic murine gammaherpesvirus of all the so far tested ones, (ii) suggest that some of the genes deleted in MHV-76 might be responsible for the oncogenicity of murine gammaherpesviruses, (iii) confirm that viral ORF73 is one of major latency-associated genes that is suppressed during virus reactivation, and (iv) present MHV-76 as another murine gammaherpesvirus useful as a model for study of gammaherpesvirus pathogenesis, oncogenicity, latency and reactivation.

**Keywords:** murine gammaherpesvirus; latent infection; reactivation; oncogenicity; ORF73

### Introduction

The subfamily *Gammaherpesvirinae* of the family *Herpesviridae* in the order *Herpesvirales* includes human and animal lymphotropic herpesviruses, among them EBV, KSHV, and MHV-68 (Davison *et al.*, 2009). The latter virus, isolated from a small rodent *Myodes glareolus* in 1976 in Slovakia

(Blaškovič *et al.*, 1980), was classified to a new species, *Murid herpesvirus 4* in the *Rhadinovirus* genus (Murphy *et al.*, 1995). Similar viruses, isolated at the same time or later from various small rodents (MHV-60, MHV-72, MHV-76, MHV-78, MHV-Šumava, MHV-4556, and MHV-5682), remain so far unclassified (Blaškovič *et al.*, 1980; Mistríková and Blaškovič, 1985; Kožuch *et al.*, 1993). They are considered as murine gammaherpesviruses more or less differing from MHV-68 in genetical, pathogenetical and immunological properties (Mistríková *et al.*, 1985, 1996, 2004; Kožuch *et al.*, 1993; Oda *et al.*, 2005; Blaškovičová *et al.*, 2007). Analysis of gene expression in MHV-68 revealed that K3, RTA, M8, and DNA polymerase genes are expressed in lytic phase, while M2, M3, M9, M11, ORF73, and ORF74 genes are expressed during latency (Rochford *et al.*, 2001). ORF73 encodes the latency-associated nuclear antigen (LANA), which plays roles in replication of latent viral episome and maintenance of latency in spleen fol-

\*Corresponding author. E-mail: virumis@savba.sk, fax: +4212-65429064.

**Abbreviations:** EBV = Epstein-Barr virus; KSHV = Kaposi's sarcoma-associated herpesvirus; IFA = immunofluorescence assay; PMA = phorbol 12-myristate 13-acetate; DMSO = dimethylsulfoxide; LANA = latency-associated nuclear antigen; MHV-60, MHV-72, MHV-68, MHV-76, MHV-78, MHV-Šumava, MHV-4556, MHV-5682 = murine gammaherpesviruses 60, 68, 76, 78, Šumava, 4556, and 5682, respectively

lowing intranasal (i.n.) infection (Virgin *et al.*, 1997; Marques *et al.*, 2003; Moorman *et al.*, 2003; Fowler *et al.*, 2003).

The ability to induce tumors in mice is a very important but differently expressed feature of most murine gamma-herpesviruses as demonstrated by various percentage of inoculated mice which developed tumors: 7% (MHV-78), 9% (MHV-68), 11% (MHV-72), 14.5% (MHV-Šumava), and 22% (MHV-60) (Mrmusová-Šupolíková *et al.*, 2003; Sunil-Chandra *et al.*, 1994; Mistríková *et al.*, 1996, 2002; Pappová *et al.*, 2004). On the other hand, MHV-76 did not exert any oncogenicity in mice (Chalupková *et al.*, 2008). Virus-induced tumors could be used for derivation of cell lines harboring viral genome and representing a latent viral infection, as shown by S11 and NB-78 cell lines carrying MHV-68 and MHV-78, respectively (Usherwood *et al.*, 1996; Mistríková *et al.*, 2006). The course of MHV-76 infection in mice showed a route-dependent manner; as this virus induced latency in the spleen after intraperitoneal but not intranasal inoculation. In contrast, both routes of infection led to latency with MHV-68 (Macrae *et al.*, 2001; Clambey *et al.*, 2002).

In this work, we attempted (i) to establish cell lines latently infected with MHV-76 differing from other murine gammaherpesviruses in several important properties, (ii) characterize them regarding phenotype, growth properties, latency and virus reactivation, and (iii) examine their possible tumorigenicity.

## Materials and Methods

**Viruses.** MHV-68 and MHV-76 stocks were prepared in Vero cells by infection at MI of 1, harvesting at 72–96 hrs p.i., sonication, clarification by low-speed centrifugation, and storage at -70°C.

**Cells.** HeLa and non-tumorigenic HeLa-human skin fibroblast hybrid CGL1 cells (Stanbridge, 1976) as well as latently MHV-76-infected  $\lambda$ HeLa,  $\lambda$ CGL1, and SP2/0 cells and thymocytes were grown in DMEM with 7% FCS and antibiotics. Thymocytes explanted from thymuses of BALB/c mice, mouse myeloma SP2/0 cell line, and NB-78 cell line were prepared or cultured as described (Horibata and Harris, 1970; Mistríková *et al.*, 2006).

**Mice.** BALB/c mice were supplied by the Faculty of Veterinary Medicine, Brno, Czech Republic.

**Experiments on mice.** A group of 17 newborn mice was inoculated subcutaneously in cervical area with  $10^5$   $\lambda$ HeLa cells per mouse in 20  $\mu$ l. A control group of 10 newborn mice was inoculated similarly with HeLa cells. The mice were killed 30 days p.i. by cervical dislocation under ether anesthesia and their lungs and spleens were removed, homogenized and stored at -70°C until use.

**Virus titration.** Frozen homogenates of organs were thawed, clarified by low-speed centrifugation, diluted in DMEM supplemented with 2% of heat-inactivated bovine serum, 300  $\mu$ g/ml glutamine, and 80  $\mu$ g/ml gentamicin, and titrated on Vero cell monolayer cultures. CPE was read after 3–7 days of incubation at

37°C in 5% CO<sub>2</sub> and hematoxylin-eosin staining. Virus infectivity titers were expressed in TCID<sub>50</sub>/ml.

**Immunofluorescence assay (IFA)** of viral particle antigen was done by an indirect method. Briefly, cells in suspension were stained with a polyclonal rabbit antibody to MHV-68 followed by a FITC-conjugated anti-rabbit antibody (ALEXA 488, Molecular Probes, USA). Washing with PBS was included in between individual steps. Finally, cells were mounted and examined under fluorescence microscope. The percentage of positive cells was calculated.

**PCR for viral DNA** was carried out as described. Total DNA was isolated from tissues or cells using the DNeasy Tissue Kit (Qiagen) according to the manufacturer's instructions. The reaction mixture based on the GoTaq Green Master Mix (Promega) contained total DNA, and the primers specific for MHV-68 ORF4 gene 5'-CAAATGCCACACTAACATCTCCTAAA-3' (forward) and 5'-AGTATATAGGCTGGGGACTTGACTTCG-3' (reverse) (Sigma-Aldrich). Positive control contained MHV-68 DNA, while negative one lacked template DNA. The reaction consisted of initial denaturation at 84°C for 3 mins, 40 cycles of 94°C/1 min, 65°C/1 min, and 72°C/1 min, and final extension at 72°C for 3 mins. PCR products were analyzed by electrophoresis in 1.2% agarose gels and ethidium bromide staining. The expected size of specific PCR product was 410 bp.

**Reactivation of latent virus.** PMA was added to one-day-old cultures of latently infected cells to final concentration of 20 ng/ml. After 24 hrs, cells were harvested and used for assaying viral ORF73 gene expression and infectious virus.

**RT-PCR for viral ORF73 gene transcripts** was carried out as followed. Total RNA was isolated using the Instapure System (Eurogentec, Belgium), dissolved in DEPC-treated water and reverse-transcribed with M-MuLV reverse transcriptase (Finnzymes OY) using random heptanucleotide primers. The reaction mixture for a nested PCR contained the GoTaq Green Master Mix, 5% DMSO and primers. Both PCRs consisted of initial denaturation at 95°C for 5 mins, 35 cycles of 95°C/45 secs, 59°C/40 secs, and 72°C/30 secs, and final extension at 72°C for 5 mins. Outer primers 5'-TAG TACCTTCTACGCTGCTC-3' (forward) and 5'-GTAGGTGCT TCAACAAACCA-3' (reverse), and inner primers 5'-CCAA GGGTAAACAGCTAACT-3' (forward) and 5'-CCTTCATCA CCAGTACATGAG-3' (reverse) were employed. A positive control consisted of MHV-68 DNA, while a negative one lacked template DNA. Final PCR products were analyzed by electrophoresis in 1.2% agarose gels and ethidium bromide staining. The expected size of specific PCR product was 363 bp.

## Results

### *Establishment and characterization of latently infected cell lines*

Using infection with MHV-76 at MI of 0,01 and frequent passaging of infected cells in standard culture medium two latently infected cell lines were established, namely  $\lambda$ CGL1 and  $\lambda$ HeLa. Use of higher MI resulted in cell destruction due to viral CPE and the inability to undergo passaging (data not shown). Cytological investigation revealed a changed




Fig. 1

**Detection of viral DNA (ORF4 gene) in latently infected cell lines**

CGL1 cells (lane 1);  $\lambda$ CGL1 cells, passages 21 (lane 2), 34 (lane 3), and 72 (lane 4); HeLa cells (lane 5);  $\lambda$ HeLa cells, passages 24 (lane 6), 38 (lane 7), 56 (lane 8), and 83 (lane 9); MHV-68 DNA, positive control (lane 10); PCR without template DNA, negative control (lane 11); DNA ladder (lane L).




Fig. 2

**Suppression of viral ORF73 gene in latently infected cell lines following PMA treatment**

The RT-PCR product consisted of 363 bp. DNA ladder (lane L);  $\lambda$ CGL1 cells (lane  $\lambda$ 1); CGL1 cells treated with PMA (lane  $\lambda$ 1p);  $\lambda$ HeLa cells (lane  $\lambda$ H);  $\lambda$ HeLa cells treated with PMA (lane  $\lambda$ Hp); NB-78 cells (lane NB); NB-78 cells treated with PMA (lane NBp); PCR with no template DNA, negative control (lane C-); PCR with MHV-68 DNA, positive control (lane C+).

phenotype of latently infected cells and inability to form continuous monolayer (data not shown). Viral DNA was demonstrated by PCR regularly in passages of both latently infected cell lines (Fig. 1).

Viral latency-associated ORF73 gene was expressed in both latently infected cells lines (Fig. 2). Treatment of the latently infected cells with PMA, an agent causing virus reactivation, resulted in suppression of this gene and appearance of infectious virus in the medium (Table 1). A similar effect of PMA could be also seen in NB-78 cells latently infected with MHV-78.

Viral particle antigen indicating spontaneous virus reactivation was observed irregularly in passages of both latently infected cell lines (data not shown).

**Table 1. Infectious virus produced by latently infected cells following PMA treatment**

Cells					
$\lambda$ CGL1	$\lambda$ CGL1+PMA	$\lambda$ HeLa	$\lambda$ HeLa+PMA	NB-78	NB-78+PMA
-	+	-	++	-	+

Infectious virus absent (-) or present in undiluted (+) or  $10^{-1}$  diluted (++) culture medium, respectively.




Fig. 3

**Effect of latent MHV-76 infection on the growth of Lambda CGL1 and Lambda HeLa cells**

Analysis of cell growth in culture for 100 hrs revealed no differences between the latently infected  $\lambda$ CGL1 and  $\lambda$ HeLa cells and non-infected parental CGL1 and HeLa cells, respectively (Fig. 3). SP2/0 cells latently infected with MHV-76 or MHV-68, used for comparison, also did not differ from their non-infected counterparts in the growth during 47 passages (Fig. 4). On the other hand, a latent MHV-76 infection positively affected the growth of thymocytes in culture as they reached 17 passages compared to 11 passages of non-infected thymocytes. In contrast, a latent MHV-68 infection did not have any effect on the growth of thymocytes in culture (Fig. 5).

Using a similar approach a latent MHV-76 infection was also established in SP2/0 cell line and cultured thymocytes (data not shown).




Fig. 4

**Effect of latent MHV-76 or MHV-68 infection on the growth of SP2/0 cells**

Final cell count in individual passages was estimated.




Fig. 5

Effect of latent MHV-76 or MHV-68 infection on the growth of thymocytes

#### Non-tumorigenicity of $\lambda$ HeLa cells

Inoculation of  $\lambda$ HeLa cells carrying MHV-76 genome into mice did not lead to development of tumors in the inoculation area. We could not detect either viral DNA or infectious virus in the spleen and lungs or viral antigen in the splenocytes of these mice (data not shown).

#### Discussion

Latently infected cell lines provide useful system for study of latency and molecular characteristics of viral infection. A very common way how to obtain such a system is derivation of cell lines from tumor tissues. In general, viral genome can be present in these cell lines or not. For example, there are EBV genome-negative cell lines such as BJA-B, U-698M, and U-715M (Pagano *et al.*, 1973; Klein *et al.*, 1974; Nilsson *et al.*, 1974; Menézes *et al.*, 1975).

Also tumors originating from mice infected with some murine gammaherpesviruses have been used for derivation of cell lines. So Usherwood *et al.* (1996) obtained from tumors of mice infected with MHV-68 five cell lines, of which only one, S11 was viral genome-positive, while four were negative. Using MHV-78 and a similar approach Mistríková *et al.* (2006) obtained a single cell line, NB-78, which was viral genome-positive.

Since MHV-76 infection did not lead to tumor development in mice (Chalupková *et al.*, 2008), we had to employ another way of obtaining a cell line carrying MHV-76 genome. It was infection of selected cell lines, CGL1 and HeLa, at a low multiplicity (0.01 TCID<sub>50</sub>/cell) and their regular passaging that led to latently infected cell lines  $\lambda$ CGL1 and  $\lambda$ HeLa. Both of them showed a changed phenotype and were continuously MHV-76 genome-positive.

The analysis of cell growth in culture revealed that the latent infection with MHV-76 did not influence CGL1 and HeLa cell lines in this regard. Since MHV-76 is a lymphotropic virus, we also investigated its effect on the growth of thymocytes in culture. We found that the growth and survival of thymocytes latently infected with MHV-76 were markedly stimulated. Likewise, Steinitz *et al.* (1975) demonstrated a stronger proliferation of EBV genome-positive compared to EBV genome-negative cells.

As for the potential oncogenicity of MHV-76, we showed here that inoculation of  $\lambda$ HeLa cells into mice did not lead to tumor development. In contrast, NB-78 cells carrying MHV-78 we shown to induce tumors under the same conditions (Mrmusová-Šupolíková *et al.*, 2003). In the study of Daibata *et al.* (1996), EBV-positive cell lines derived from mantle cell lymphoma induced tumors in nude mice, while a lymphoblastoid B-cell line, established by infecting normal B-lymphocytes *in vitro* with EBV, did not. All these results indicate that besides possible differences between viruses also those between cells containing virus or carrying viral genome might contribute to viral oncogenicity. As for the oncogenicity of various murine gammaherpesviruses, all the so far obtained results support the view that MHV-76 is the only non-oncogenic one.

Since we did not detect viral DNA or infectious virus in the spleen and lungs or viral antigen in the splenocytes of the mice inoculated with  $\lambda$ HeLa cells, we assume that there was neither productive nor latent infection with possible virus reactivation.

Summing up, we established two cell lines latently infected with MHV-76, characterized them, and confirmed non-oncogenicity of MHV-76 and the essential role of ORF73 gene in maintenance of latency of murine gammaherpesviruses.

**Acknowledgement.** This work was supported by the grant No. 1/0083/08 from the Scientific Grant Agency of Ministry of Education of Slovak Republic and Slovak Academy of Sciences.

#### References

- Blašková D, Stančeková M, Svobodová J, Mistríková J (1980): Isolation of five strains of herpesviruses from two species of free living small rodents. *Acta Virol.* 24, 468.
- Blašková J, Tomášková J, Šupolíková M, Mistríková J, Kopáček J (2007): Sequence analysis of the regions flanking terminal repeats of the genome of Šumava isolate of murine gammaherpesvirus. *Acta Virol.* 51, 143–148.
- Chalupková A, Hricová M, Hrabovská Z, Mistríková J (2008): Pathogenetical characterization of MHV-76: a spontaneous 9,5-kilobase-deletion mutant of murine lymphotropic gammaherpesvirus 68. *Acta Vet. (Brno)* 77, 231–237. doi:10.2754/avb200877020231

- Clambey, ET, Virgin IV, HW, Speck, SH (2002): Characterization of a spontaneous 9.5-kilobase-deletion mutant of murine gammaherpesvirus 68 reveals tissue-specific genetic requirements for latency. *J. Virol.* 76, 6532–6544. doi:10.1128/JVI.76.13.6532-6544.2002
- Daibata M, Kubonishi I, Miyoshi I (1996): Differential Tumorigenicity between Epstein-Barr Virus Genome-Positive and Genome-Negative Cell Lines with t(11;14)(q13;q32) Derived from Mantle Cell Lymphoma. *J. Virol.* 70, 9003–9007.
- Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ, Minson AC, Pellett PE, Roizman B, Studdert MJ, Thiry E (2009): The order Herpesvirales. *Arch. Virol.* 154, 171–177. doi:10.1007/s00705-008-0278-4
- Fowler P, Marques S, Simas JP, Efstathiou S (2003): ORF 73 of murine herpesvirus 68 is critical for the establishment and maintenance of latency. *J. Gen. Virol.* 84, 3405–3416. doi:10.1099/vir.0.19594-0
- Horibata K, Harris AW (1970): Mouse myelomas and lymphomas in culture. *Exp. Cell Res.* 60, 61–77. doi:10.1016/0014-4827(70)90489-1
- Klein G, Lindahl T, Jondal M, Leibold W, Menézes J, Nilsson K, Sunström C (1974): Continuous lymphoid cell lines with characteristics of B cells (Bone-Marrow-Derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. *Proc. Natl. Sci. Acad. USA.* 71, 3283–3286. doi:10.1073/pnas.71.8.3283
- Kožuch O, Reichel M, Leško J, Remeňová A, Labuda M, Lysý J, Mistríková J (1993): Further isolation of murine herpesviruses from small mammals in southwestern Slovakia. *Acta Virol.* 37, 101–105.
- Macrae AI, Dutia BM, Milligan S, Brownstein DG, Allen DJ, Mistríková J, Davison AJ, Nash AA, Stewart JP (2001): Analysis of a novel strain of murine gammaherpesvirus reveals a genomic locus important for acute pathogenesis. *J. Virol.* 75, 5315–5327. doi:10.1128/JVI.75.11.5315-5327.2001
- Marques S, Efstathiou S, Smith KG, Haury M, Simas, JP (2003): Selective gene expression of latent murine gammaherpesvirus 68 in B-lymphocytes. *J. Virol.* 77, 7308–7318. doi:10.1128/JVI.77.13.7308-7318.2003
- Menézes J, Leibold W, Klein G, Clements G (1975): Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. *Biomedicine.* 22, 276–284.
- Mistríková J, Blaškovič D (1985): Ecology of the murine alphaherpesvirus and its isolation from lungs of rodents in cell culture. *Acta Virol.* 29, 312–317.
- Mistríková J, Rajčáni J, Mrmusová M, Oravcová I (1996): Chronic infection of BALB/c mice with murine herpesvirus 72 associated with neoplasm development. *Acta Virol.* 40, 297–301.
- Mistríková J, Mrmusová Šupolíková M, Rajčáni J (2004): Leukemia-like syndrome in Balb/c mice infected with the lymphotropic gamma herpesvirus MHV-Sumava: an analogy to EBV infection. *Neoplasma* 51, 71–76.
- Mistríková J, Blaškovičová J, Pappová M, Hricová M (2006): Establishment and characterization of a tumor cell line derived from a mouse infected with murine gammaherpesvirus 78. *Acta Virol.* 50, 223–228.
- Moorman NJ, Willer DO, Speck SH (2003): The Gammaherpesvirus 68 Latency-Associated Nuclear Antigen Homolog Is Critical for the Establishment of Splenic Latency. *J. Virol.* 77, 10295–10303. doi:10.1128/JVI.77.19.10295-10303.2003
- Mrmusová Šupolíková M, Pappová M, Mistríková J (2003): Pathogenesis of murine lymphotropic gammaherpesvirus isolate 78. *Acta Vet. (Brno)* 72, 371–376.
- Nilsson K, Sundström C (1974): Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. *Int. J. Cancer.* 13, 808–823. doi:10.1002/ijc.2910130609
- Oda W, Mistríková J, Stančeková M, Dutia BM, Nash AA, Takahata H, Jin Z, Oka T, Hayashi K (2005): Analysis of genomic homology of murine gammaherpesvirus (MHV)-72 to MHV-68 and impact of MHV-72 on the survival and tumorigenesis in the MHV-72-infected CB17 scid/scid and CB17+/+ mice. *Pathol. Int.* 55, 558–568. doi:10.1111/j.1440-1827.2005.01869.x
- Pagano JS, Nonoyama M, Huang CH (1973): Epstein-Barr virus in human cells. In *Possible Episomes in Eukaryotes*. Proc. Fourth Lepetit Coll North-Holland Publ. Co. Amsterdam, pp. 218–228.
- Pappová M, Stančeková M, Spiššáková I, Ďurmanová V, Mistríková J (2004): Pathogenetical characterization of isolate MHV-60 of mouse herpesvirus strain 68. *Acta Virol.* 48, 91–96.
- Rochford R, Lutzke ML, Alfinito RF, Clavo A, Cardin RD (2001): Kinetics of Murine Gammaherpesvirus 68 Gene Expression following Infection of Murine Cells in Culture and in Mice. *J. Virol.* 75, 4955–4963. doi:10.1128/JVI.75.11.4955-4963.2001
- Stanbridge EJ (1976): Suppression of malignancy in human cells. *Nature* 260, 17–20. doi:10.1038/260017a0
- Steinitz M, Klein G (1975): Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro. *Proc. Natl. Acad. Sci. USA.* 72, 3518–3520. doi:10.1073/pnas.72.9.3518
- Sunil-Chandra NP, Arno J, Fazakerley J, Nash AA (1994): Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68. *Am. J. Pathol.* 145, 818–826.
- Usherwood EJ, Stewart JP, Nash AA (1996): Characterization of tumor cell lines derived from murine gammaherpesvirus-68-infected mice. *J. Virol.* 70, 6516–6518.
- Virgin IV HW, Latreille P, Wamsley P, Hallsworth K, Weck KE, Canto AJD, Speck SH (1997): Complete sequence and genomic analysis of murine gammaherpesvirus 68. *J. Virol.* 71, 5894–5904.
- Waltzek TB, Kelley GO, Alfaro ME, Kurobe T, Davison AJ, Hedrick RP (2009): Phylogenetic relationships in the family Alloherviridae. *Dis. Aquat. Org.* 84, 179–194. doi:10.3354/dao02023